PL1669367T3 - Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1) - Google Patents

Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1)

Info

Publication number
PL1669367T3
PL1669367T3 PL04742049T PL04742049T PL1669367T3 PL 1669367 T3 PL1669367 T3 PL 1669367T3 PL 04742049 T PL04742049 T PL 04742049T PL 04742049 T PL04742049 T PL 04742049T PL 1669367 T3 PL1669367 T3 PL 1669367T3
Authority
PL
Poland
Prior art keywords
tgf
peptides
bind
growth factor
transforming growth
Prior art date
Application number
PL04742049T
Other languages
English (en)
Inventor
De Las Herrerias Javier Dotor
Vazquez Ana Belén Lopez
Sagastibelza Juan José Lasarte
Valtuena Jesus Prieto
Cuesta Francisco Borras
Original Assignee
Proyecto De Biomedicina Cima S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S L filed Critical Proyecto De Biomedicina Cima S L
Publication of PL1669367T3 publication Critical patent/PL1669367T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04742049T 2003-08-22 2004-07-05 Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1) PL1669367T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200302020A ES2304069B1 (es) 2003-08-22 2003-08-22 Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
PCT/ES2004/000320 WO2005019244A1 (es) 2003-08-22 2004-07-05 Péptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-beta1)
EP04742049A EP1669367B1 (en) 2003-08-22 2004-07-05 Peptides which can bind to transforming growth factor beta 1 (tgf-beta1)

Publications (1)

Publication Number Publication Date
PL1669367T3 true PL1669367T3 (pl) 2011-02-28

Family

ID=34203356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04742049T PL1669367T3 (pl) 2003-08-22 2004-07-05 Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1)

Country Status (18)

Country Link
US (1) US7666841B2 (pl)
EP (1) EP1669367B1 (pl)
JP (1) JP4902352B2 (pl)
CN (1) CN100424093C (pl)
AT (1) ATE479702T1 (pl)
AU (2) AU2004266856A1 (pl)
BR (1) BRPI0413215A (pl)
CA (1) CA2535807A1 (pl)
CY (1) CY1110885T1 (pl)
DE (1) DE602004028949D1 (pl)
DK (1) DK1669367T3 (pl)
ES (2) ES2304069B1 (pl)
HR (1) HRP20100637T1 (pl)
PL (1) PL1669367T3 (pl)
PT (1) PT1669367E (pl)
RU (2) RU2333917C2 (pl)
SI (1) SI1669367T1 (pl)
WO (1) WO2005019244A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
CA2627298A1 (en) * 2005-10-24 2007-05-03 Proyecto De Biomedicina Cima, S.L. Use of tgf-.beta.1 inhibitor peptides in the preparation of an immune response modulating agent
RU2420307C2 (ru) * 2005-10-24 2011-06-10 Проекто Де Биомедисина Сима, С.Л. ПРИМЕНЕНИЕ ИНГИБИРУЮЩИХ TGF-бета1 ПЕПТИДОВ ДЛЯ ПРИГОТОВЛЕНИЯ МОДУЛИРУЮЩЕГО ИММУННЫЙ ОТВЕТ АГЕНТА
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
US20120225933A1 (en) 2009-11-05 2012-09-06 Gonzalez Aseguinolaza Gloria Regulated expression systems
RU2413769C1 (ru) * 2009-12-24 2011-03-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pET-32a, КОДИРУЮЩАЯ ГЕН ЛИГАНД-СВЯЗЫВАЮЩЕГО ДОМЕНА РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА-β ЧЕЛОВЕКА (TβRII), ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ СЛИТНОГО БЕЛКА ТИОРЕДОКСИН/TβRII И СПОСОБ РЕНАТУРАЦИИ И ОЧИСТКИ ЦЕЛЕВОГО БЕЛКА TβRII
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
KR101029705B1 (ko) * 2010-06-30 2011-04-18 (주)엔솔테크 신규 펩타이드 및 그 용도
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
CA2857073A1 (en) 2011-11-28 2013-06-06 Institucio Catalana De Recerca I Estudis Avancats Methods and kits for the prognosis of colorectal cancer
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
EP2917365B1 (en) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Methods and kits for the prognosis of colorectal cancer
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
JP6730701B2 (ja) 2013-11-14 2020-07-29 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
US10980787B2 (en) 2015-12-24 2021-04-20 The Doshisha Drug for treating or preventing disorder caused by TGF-B signals, and application thereof
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
MXPA05004563A (es) * 2002-11-01 2005-07-26 Boys Town Nat Res Hospital Ligando inducible para la integrina alfa1beta1 y usos.

Also Published As

Publication number Publication date
RU2008115678A (ru) 2009-10-27
WO2005019244A1 (es) 2005-03-03
PT1669367E (pt) 2010-12-07
AU2010212466A1 (en) 2010-09-09
RU2455358C2 (ru) 2012-07-10
ATE479702T1 (de) 2010-09-15
ES2351865T3 (es) 2011-02-11
CN100424093C (zh) 2008-10-08
CA2535807A1 (en) 2005-03-03
CY1110885T1 (el) 2015-06-10
HRP20100637T1 (hr) 2010-12-31
EP1669367B1 (en) 2010-09-01
AU2010212466B2 (en) 2012-07-19
DE602004028949D1 (en) 2010-10-14
ES2304069A1 (es) 2008-09-01
SI1669367T1 (sl) 2010-11-30
EP1669367A1 (en) 2006-06-14
AU2004266856A1 (en) 2005-03-03
JP4902352B2 (ja) 2012-03-21
BRPI0413215A (pt) 2007-06-19
CN1839149A (zh) 2006-09-27
RU2333917C2 (ru) 2008-09-20
ES2304069B1 (es) 2009-08-12
JP2007525204A (ja) 2007-09-06
US7666841B2 (en) 2010-02-23
RU2006109011A (ru) 2006-07-27
DK1669367T3 (da) 2010-11-08
US20070142275A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
CY1110885T1 (el) Πεπτιδια που μπορουν να συνδεθουν στον αυξητικο παραγοντα μεταμορφωσης βητα 1 (tgf-beta1)
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE539083T1 (de) Promotoren zur regulierung der genexpression in pflanzenwurzeln
EP1660682A4 (en) ANTISENSE MODULATION OF P38 MITOGEN-ACTIVATED PROTEIN KINASE EXPRESSION
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
DK1692517T3 (da) Anvendelse af ADAM 12 til diagnosticering af præeklampsi
IL157464A0 (en) Zinc finger binding domains for nucleotide sequence ann
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
WO2005040339A3 (en) Aptamers to human epidermal growth factor receptor-3
AU2003230144A8 (en) Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
DE60336746D1 (de) Trimer-proteine zur trimer-zytokine
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
PL1704237T3 (pl) Ccamk biorąca udział w nodulacji i endomikoryzacji
EP1494702A4 (en) COMPOSITION FOR STIMULATION OF NEW BONE INDUCTION
WO2004028447A3 (en) Novel compositions and methods for the treatment of psoriasis
ATE461274T1 (de) Einen internen reinigungsmarker enthaltende glutamin:fructose-6-phosphat- amidotransferase (gfat) und verwendung davon zum screening von verbindungen
ATE516364T1 (de) Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5